These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 35222030)

  • 1. Effectiveness of Antiviral Therapy in Highly-Transmissible Variants of SARS-CoV-2: A Modeling and Simulation Study.
    Schöning V; Kern C; Chaccour C; Hammann F
    Front Pharmacol; 2022; 13():816429. PubMed ID: 35222030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molnupiravir (MK-4482) is efficacious against Omicron and other SARS-CoV-2 variants in the Syrian hamster COVID-19 model.
    Rosenke K; Okumura A; Lewis MC; Feldmann F; Meade-White K; Bohler WF; Griffin A; Rosenke R; Shaia C; Jarvis MA; Feldmann H
    bioRxiv; 2022 Feb; ():. PubMed ID: 35233571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Trimeric Artesunate Analog TF27, a Broadly Acting Anti-Infective Model Drug, Exerts Pronounced Anti-SARS-CoV-2 Activity Spanning Variants and Host Cell Types.
    Hahn F; Wangen C; Häge S; Herrmann L; Herrmann A; Tsogoeva SB; Marschall M
    Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Will vaccine-derived protective immunity curtail COVID-19 variants in the US?
    Mancuso M; Eikenberry SE; Gumel AB
    Infect Dis Model; 2021; 6():1110-1134. PubMed ID: 34518808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 Variants of Concern.
    Choi JY; Smith DM
    Yonsei Med J; 2021 Nov; 62(11):961-968. PubMed ID: 34672129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molnupiravir Does Not Induce Mutagenesis in Host Lung Cells during SARS-CoV-2 Treatment.
    Githaka JM
    Bioinform Biol Insights; 2022; 16():11779322221085077. PubMed ID: 35342288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences.
    Singla S; Goyal S
    Bull Natl Res Cent; 2022; 46(1):62. PubMed ID: 35287311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replication Kinetics of B.1.351 and B.1.1.7 SARS-CoV-2 Variants of Concern Including Assessment of a B.1.1.7 Mutant Carrying a Defective ORF7a Gene.
    Pyke AT; Nair N; van den Hurk AF; Burtonclay P; Nguyen S; Barcelon J; Kistler C; Schlebusch S; McMahon J; Moore F
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34200386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.
    Park SJ; Yu KM; Kim YI; Kim SM; Kim EH; Kim SG; Kim EJ; Casel MAB; Rollon R; Jang SG; Lee MH; Chang JH; Song MS; Jeong HW; Choi Y; Chen W; Shin WJ; Jung JU; Choi YK
    mBio; 2020 May; 11(3):. PubMed ID: 32444382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Molnupiravir and Nirmatrelvir Treatment Improves the Inhibitory Effect on SARS-CoV-2 in Rhesus Macaques.
    Rosenke K; Lewis MC; Feldmann F; Bohrnsen E; Schwarz B; Okumura A; Bohler WF; Callison J; Shaia C; Bosio CM; Lovaglio J; Saturday G; Jarvis MA; Feldmann H
    bioRxiv; 2022 Sep; ():. PubMed ID: 36263071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent.
    Lee CC; Hsieh CC; Ko WC
    Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence.
    Tatsi EB; Filippatos F; Michos A
    Epidemiol Infect; 2021 Nov; 149():e237. PubMed ID: 34732275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Plitidepsin, an inhibitor of the cell elongation factor eEF1a, and molnupiravir an analogue of the ribonucleoside cytidine, two new chemical compounds with intense activity against SARS-CoV-2].
    Reina J
    Rev Esp Quimioter; 2021 Oct; 34(5):402-407. PubMed ID: 33902254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-COV-2 Variants: Differences and Potential of Immune Evasion.
    Hirabara SM; Serdan TDA; Gorjao R; Masi LN; Pithon-Curi TC; Covas DT; Curi R; Durigon EL
    Front Cell Infect Microbiol; 2021; 11():781429. PubMed ID: 35118007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Development of SARS-CoV-2 Variants: The Gene Makes the Disease.
    Perez-Gomez R
    J Dev Biol; 2021 Dec; 9(4):. PubMed ID: 34940505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants.
    Chakraborty C; Sharma AR; Bhattacharya M; Agoramoorthy G; Lee SS
    mBio; 2021 Aug; 12(4):e0114021. PubMed ID: 34465019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 Spike Pseudoviruses: A Useful Tool to Study Virus Entry and Address Emerging Neutralization Escape Phenotypes.
    Kalkeri R; Cai Z; Lin S; Farmer J; Kuzmichev YV; Koide F
    Microorganisms; 2021 Aug; 9(8):. PubMed ID: 34442823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H.
    Zeng C; Evans JP; Faraone JN; Qu P; Zheng YM; Saif L; Oltz EM; Lozanski G; Gumina RJ; Liu SL
    mBio; 2021 Oct; 12(5):e0251021. PubMed ID: 34607452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of Molnupiravir in COVID-19 patients: a systematic review.
    Mali KR; Eerike M; Raj GM; Bisoi D; Priyadarshini R; Ravi G; Chaliserry LF; Janti SS
    Ir J Med Sci; 2023 Aug; 192(4):1665-1678. PubMed ID: 36087236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.